Skip to main content

Table 3 Summary of adverse events (overall study population)

From: Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

Outcome Number of patients (%)
  N = 103  
All grades Grade 3 or 4 Grade 5
TEAEs 99 (96) 38 (37) 3 (3)
Study drug-related TEAEs 87 (84) 16 (16) 0
Related TEAEs with rate ≥ 10%    
Decreased white blood cell count 17 (17) 0 0
Asthenia 17 (17) 0 0
Rash 16 (16) 1 (1) 0
Hypothyroidism 16 (16) 0 0
Hyperthyroidism 12 (12) 0 0
Decreased neutrophil count 12 (12) 1 (1) 0
Anemia 12 (12) 5 (5) 0
SAEs 27 (26) 20 (19) 3 (3)
Related SAEs 10 (10) 9 (9) 0
Related TEAEs leading to discontinuation 3 (3) 3 (3) 0
irAEs 44 (43) 8 (8) 0
irAEs leading to discontinuation 3 (3) 3 (3) 0
Injection site reactions 9 (9) 0 0
 Injection site pain 2 (2) 0 0
 Injection site reaction 6 (6) 0 0
 Injection site swelling 1 (1) 0 0
  1. AE, adverse event; irAE, immune-related adverse event; SAE, serious adverse event; TEAE, treatment-emergent adverse event
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us